Factor VIII Level Test at Ayzal Lab

Factor VIII Level at Ayzal Lab

The Factor VIII Level test is a specialized hematological laboratory investigation that measures the activity of Factor VIII, an essential blood-clotting protein. Also known as antihemophilic factor (AHF), Factor VIII plays a critical role in the intrinsic pathway of the coagulation cascade. When a blood vessel is injured, a complex sequence of chemical reactions occurs to form a stable blood clot and prevent excessive bleeding. Factor VIII acts as a cofactor for activated Factor IX, working together to activate Factor X, which ultimately leads to the conversion of fibrinogen to fibrin, the structural backbone of a blood clot. Ayzal Lab, located in Lahore, Pakistan, offers this sophisticated coagulation assay to assist clinicians in diagnosing, monitoring, and managing complex bleeding and clotting disorders.

This laboratory test is performed using advanced automated coagulation analyzers that utilize functional clotting assays, chromogenic methods, or immunologic techniques to determine the precise level of Factor VIII activity in a patient’s plasma. The primary clinical value of this test lies in its ability to diagnose Hemophilia A, an inherited X-linked bleeding disorder caused by a deficiency or dysfunction of Factor VIII. Additionally, evaluating Factor VIII levels is vital in investigating unexplained prolonged activated partial thromboplastin time (aPTT), evaluating patients with a personal or family history of abnormal bleeding, and monitoring the efficacy of replacement therapy in hemophilia patients. Conversely, elevated levels of Factor VIII are clinically significant as they are recognized as an independent risk factor for venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism, making this test highly valuable in thrombophilia workups.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure the clinical accuracy of coagulation testing, as Factor VIII is an acute-phase reactant that can be temporarily elevated by physical stress, exercise, or inflammation. Patients undergoing a Factor VIII Level test at Ayzal Lab should observe the following guidelines:

• Fasting Requirements: While strict fasting is generally not required, patients are advised to avoid fatty meals for at least 4 to 6 hours before the blood draw to prevent lipemia, which can interfere with optical coagulation analyzers.
• Medication Review: It is crucial to inform the healthcare provider and the laboratory staff of all medications, supplements, and therapies currently being taken. Anticoagulants such as heparin, warfarin, direct oral anticoagulants (DOACs), and factor replacement therapies can significantly affect test results.
• Timing of the Test: If the test is being performed to monitor Factor VIII replacement therapy, the blood sample must be drawn at specific times (e.g., immediately before a dose for trough levels, or at a specified interval after infusion for peak levels) as directed by the hematologist.
• Avoid Physical Stress: Patients should avoid strenuous physical exercise, heavy lifting, and severe emotional stress for at least 24 hours prior to the test, as these factors can cause a transient, physiological rise in Factor VIII levels.
• Hydration: Adequate hydration with plain water is highly recommended to facilitate easier venous access and ensure a smooth blood collection process.

During the Procedure

The Factor VIII Level test is conducted via a standard venipuncture procedure, adhering to strict clinical protocols to prevent pre-analytical errors that could compromise the coagulation assay:

• Patient Positioning: The patient is comfortably seated in a blood collection chair, and the phlebotomist inspects the arm to locate a suitable vein, typically in the antecubital fossa (the crook of the elbow).
• Aseptic Technique: The skin over the selected vein is thoroughly cleansed with an antiseptic solution (such as alcohol) and allowed to air dry completely to prevent contamination or hemolysis of the sample.
• Venipuncture and Sample Collection: A tourniquet is applied briefly to make the vein more visible. A sterile needle is inserted into the vein, and blood is drawn directly into a light blue-top tube containing 3.2% buffered sodium citrate. This specific anticoagulant is essential for coagulation testing as it reversibly binds calcium, preserving the clotting factors in an inactive state.
• Tube Filling and Mixing: The collection tube must be filled completely to the designated fill line to maintain the precise 9:1 ratio of blood to anticoagulant. Immediately after drawing, the tube is gently inverted 3 to 4 times to mix the blood with the citrate thoroughly. Vigorous shaking is strictly avoided to prevent hemolysis and premature platelet activation.
• Duration and Experience: The entire venipuncture process takes less than five minutes. Patients may feel a brief, mild pinch as the needle enters the skin, but the procedure is generally painless.
• Post-Procedure Care: After the needle is removed, gentle pressure is applied to the puncture site with a sterile cotton ball or gauze pad to stop any bleeding, followed by the application of a small bandage. Patients can resume their normal daily activities immediately.

When is a Factor VIII Level Test Performed?

Diagnosis of Hemophilia A

The most common and critical indication for ordering a Factor VIII Level test is the suspected diagnosis of Hemophilia A. This genetic disorder primarily affects males and can present with varying degrees of severity depending on the level of functional Factor VIII present in the blood. Clinicians request this test for infants or children who exhibit unusual bruising, prolonged bleeding after minor cuts, or spontaneous bleeding into joints (hemarthrosis) and muscles, as well as for individuals with a known family history of the disease to confirm carrier status or guide prenatal counseling.

Investigation of Unexplained Bleeding or Prolonged aPTT

When a patient presents with unexplained, frequent, or severe bleeding episodes—such as recurrent nosebleeds (epistaxis), heavy menstrual bleeding (menorrhagia), or excessive bleeding following dental extractions or minor surgical procedures—a coagulation profile is ordered. If the initial screening tests reveal an isolated, unexplained prolongation of the activated partial thromboplastin time (aPTT) while the prothrombin time (PT) remains normal, a Factor VIII assay is performed as part of a mixing study or factor assay panel to pinpoint the specific clotting factor deficiency.

Evaluation of Von Willebrand Disease (vWD)

Factor VIII circulates in the bloodstream bound to Von Willebrand Factor (vWF), a carrier protein that protects it from rapid degradation. In patients with Von Willebrand Disease—the most common inherited bleeding disorder—a deficiency or dysfunction of vWF often leads to a secondary, proportional decrease in Factor VIII levels. A Factor VIII Level test is routinely performed alongside vWF antigen and vWF activity assays to comprehensively evaluate patients suspected of having vWD and to differentiate between different subtypes of the disease.

Monitoring Factor VIII Replacement Therapy

For patients diagnosed with Hemophilia A who are receiving therapeutic interventions, regular monitoring of Factor VIII levels is vital. This includes patients undergoing prophylactic treatment to prevent bleeding episodes, those receiving on-demand therapy during active bleeding crises, or individuals preparing for surgical procedures. Monitoring ensures that the circulating levels of Factor VIII reach and maintain the therapeutic target range necessary to achieve effective hemostasis and to detect the development of neutralizing antibodies (Factor VIII inhibitors) that can render treatment ineffective.

Assessment of Thrombotic Risk and Hypercoagulability

While low levels of Factor VIII lead to bleeding tendencies, persistently elevated levels of Factor VIII are associated with an increased risk of thrombosis. Clinicians order this test as part of a comprehensive thrombophilia evaluation for patients who have experienced unprovoked or recurrent venous thromboembolism (VTE), deep vein thrombosis (DVT), or pulmonary embolism (PE) at a young age. Identifying elevated Factor VIII levels helps in assessing the patient’s long-term risk of recurrent clotting events and guides decisions regarding the duration of anticoagulant therapy.

What Does a Factor VIII Level Test Detect?

The Factor VIII Level test is highly sensitive and capable of detecting a wide range of clinical conditions, physiological states, and therapeutic responses, including:

• Severe Hemophilia A (Factor VIII activity level less than 1% of normal)
• Moderate Hemophilia A (Factor VIII activity level between 1% and 5% of normal)
• Mild Hemophilia A (Factor VIII activity level between 5% and 40% of normal)
• Acquired Hemophilia A (caused by autoantibodies neutralizing Factor VIII)
• Presence of specific Factor VIII inhibitors or neutralizing antibodies
• Von Willebrand Disease (Type 1, Type 2, or Type 3)
• Carrier status for the Hemophilia A genetic mutation in females
• Elevated Factor VIII levels indicating an increased risk for deep vein thrombosis (DVT)
• Elevated Factor VIII levels indicating an increased risk for pulmonary embolism (PE)
• Physiological elevations due to acute-phase reactions (inflammation, infection, tissue injury)
• Elevations associated with pregnancy or estrogen-containing oral contraceptive use
• Elevations associated with physical stress, strenuous exercise, or adrenaline release
• Response to desmopressin (DDAVP) administration in mild hemophilia or vWD
• Efficacy and recovery of infused Factor VIII concentrates
• Liver disease affecting the clearance or synthesis of coagulation proteins
• Disseminated Intravascular Coagulation (DIC) in its consumption phase
• Systemic inflammatory response syndrome (SIRS)
• Hypercoagulable states associated with chronic inflammatory diseases
• Baseline coagulation status prior to major surgical interventions
• Underlying causes of unexplained, prolonged activated partial thromboplastin time (aPTT)

Turnaround Time and Report Access at Ayzal Lab

At Ayzal Lab, we understand that timely and accurate diagnostic results are essential for effective clinical decision-making and patient peace of mind. The Factor VIII Level test is a specialized coagulation assay that requires precise laboratory handling, plasma separation, and automated analysis. Typically, the test results are processed, verified by our consultant pathologists, and made available within 24 to 48 hours of sample collection.

Ayzal Lab provides multiple convenient methods for patients and referring physicians to access diagnostic reports. Once the report is finalized, patients receive an automated SMS notification containing a secure link to download the PDF report directly to their smartphones. Additionally, reports can be accessed and downloaded anytime through the official Ayzal Lab online patient portal. For patients who prefer physical copies, printed reports can be collected directly from our main diagnostic center or designated collection points in Lahore.

Factor VIII Level Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Factor VIII Activity Level	50% to 150% of normal (or 0.50 to 1.50 IU/mL)	Decreased (<50%): Indicates Hemophilia A, Von Willebrand Disease, or acquired inhibitors. Elevated (>150%): Indicates hypercoagulability, acute inflammation, or pregnancy.
Severe Hemophilia A Classification	Not applicable (Normal activity)	Activity level < 1% of normal. Characterized by frequent spontaneous bleeding into joints and muscles.
Moderate Hemophilia A Classification	Not applicable (Normal activity)	Activity level 1% to 5% of normal. Characterized by bleeding after minor trauma or injury.
Mild Hemophilia A Classification	Not applicable (Normal activity)	Activity level 5% to 40% of normal. Bleeding usually occurs only after major trauma, surgery, or tooth extraction.
Activated Partial Thromboplastin Time (aPTT) Correlation	Normal range (typically 25 to 35 seconds)	Prolonged aPTT in the presence of decreased Factor VIII levels, correcting or failing to correct during mixing studies.
Factor VIII Inhibitor Screen	Negative (No inhibitors detected)	Positive: Indicates the presence of neutralizing antibodies (inhibitors) against Factor VIII, complicating replacement therapy.
Von Willebrand Factor (vWF) Correlation	Normal vWF antigen and activity levels	Concurrently decreased vWF and Factor VIII levels, pointing toward Von Willebrand Disease rather than isolated Hemophilia A.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Ayzal Lab for Factor VIII Level?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified hematologists, consultant pathologists, and skilled medical technologists specializing in advanced coagulation testing.
• Patient-Focused Care: We prioritize patient comfort, safety, and clear communication throughout the sample collection and reporting process.
• Quality Diagnostic Services: Ayzal Lab adheres to strict internal and external quality control protocols to ensure the highest accuracy and reliability of all specialized assays.
• Professional Reporting: Our diagnostic reports are comprehensive, easy to read, and verified by expert pathologists to assist clinicians in precise diagnosis.
• Modern Diagnostic Approach: We utilize state-of-the-art automated coagulation analyzers and advanced laboratory techniques to perform delicate factor assays.
• Comfortable Environment: Our diagnostic centers in Lahore are designed to provide a clean, hygienic, and welcoming environment for all patients.
• Convenient Location: Easily accessible facilities across Lahore make it simple for patients to undergo testing without long-distance travel.
• Commitment to Accurate Diagnosis: We are dedicated to delivering timely, precise, and clinically actionable diagnostic insights to support optimal patient outcomes.